UK's Bicycle Therapeutics Q2 net loss narrows on reduced clinical program expenses
BCYC•Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $12.00, about 210.9% above its July 29 closing price of $3.86
Outlook and pipeline
- Company expects cash runway to extend into 2030
- Bicycle Therapeutics remains on track to begin BT1702 Phase 1 trial in 2027
- Company is actively enrolling patients in Phase 2 trial for nuzefatide in recurrent pancreatic cancer
Quarterly results and expense drivers
-
UK oncology drug developer's Q2 net loss narrowed from prior year
-
Collaboration revenue for Q2 declined sharply year-over-year
-
Lower operating expenses driven by reduced clinical program and personnel costs after workforce reduction
-
LOWER CLINICAL AND PERSONNEL COSTS - Co said reduced clinical program expenses and workforce reduction drove lower R&D and G&A expenses
